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Background: Recent evidence has highlighted deficiencies in clinical trial protocols, having implications for many
groups. Existing guidelines for randomized clinical trial (RCT) protocol content vary substantially and most do not
describe systematic methodology for their development. As one of three prespecified steps for the systematic
development of a guideline for trial protocol content, the objective of this study was to conduct a three-round
Delphi consensus survey to develop and refine minimum content for RCT protocols.
Methods: Panellists were identified using a multistep iterative approach, met prespecified minimum criteria and
represented key stakeholders who develop or use clinical trial protocols. They were asked to rate concepts for
importance in a minimum set of items for RCT protocols. The main outcome measures were degree of importance
(scale of 1 to 10; higher scores indicating higher importance) and level of consensus for items. Results were
presented as medians, interquartile ranges, counts and percentages.
Results: Ninety-six expert panellists participated in the Delphi consensus survey including trial investigators,
methodologists, research ethics board members, funders, industry, regulators and journal editors. Response rates
were between 88 and 93% per round. Overall, panellists rated 63 of 88 concepts of high importance (of which 50
had a 25th percentile rating of 8 or greater), 13 of moderate importance (median 6 or 7) and 12 of low importance
(median less than or equal to 5) for minimum trial protocol content. General and item-specific comments and
subgroup results provided valuable insight for further discussions.
Conclusions: This Delphi process achieved consensus from a large panel of experts from diverse stakeholder
groups on essential content for RCT protocols. It also highlights areas of divergence. These results, complemented
by other empirical research and consensus meetings, are helping guide the development of a guideline for
protocol content.
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Reporting guidelineBackground
The protocol of a randomized clinical trial (RCT) serves
many purposes. Protocols provide investigators with a
document to guide trial conduct; trial participants with a
detailed description of trial methodology; research ethics
committees/institutional review boards (REC/IRBs) with
a foreknowledge of predefined safeguards to protect par-
ticipants’ interests and safety; research funders with a
means of assessing proposed methods; and systematic* Correspondence: jtetzlaff@ohri.ca
1Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital
Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
Full list of author information is available at the end of the article
© 2012 Tetzlaff et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orreviewers and others with a description of prespecified
methods to evaluate potential biases [1-8]. To fulfill
these purposes, protocols must be clear, detailed and
transparent.
Unfortunately, many protocols do not adequately de-
scribe important methodological details such as alloca-
tion concealment (59%) [9], primary outcomes (25%) [1],
power calculations (27%) [3] and sponsor and investiga-
tors’ roles in aspects of trial conduct [10] - all of which
have been associated with exaggerated effect sizes and
potential bias in trials. The lack of transparency and in-
complete description of methods makes critical assess-
ment of trials difficult.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Tetzlaff et al. Trials 2012, 13:176 Page 2 of 10
http://www.trialsjournal.com/content/13/1/176Reporting guidelines have been developed to help im-
prove deficiencies in research reports [11-18]. A recent
systematic review examined 40 guidelines for trial proto-
cols; only 20% included any description of their meth-
odological development process. Of those reporting
consensus methods, none described formal processes for
achieving consensus among stakeholders (for example
Nominal consensus technique, Delphi consensus) and
none described a systematic consideration of empirical
evidence for guideline development [19]. Additionally,
recommendations differed considerably across guidelines
and many did not include concepts supported by empir-
ical evidence. These inconsistencies and deficiencies
have implications for those preparing, using, and review-
ing clinical trial protocols.
An international group of researchers launched the
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) Initiative in 2007, with the primary
aim of increasing the transparency and completeness of
trial protocols. The main product of this initiative is a
checklist of key items to address in protocols of clinical
trials. This guideline is being developed with systematic
and transparent methodology.
In line with current recommendations [20], three com-
plementary methods were specified a priori to develop
the SPIRIT checklist: 1) a Delphi consensus survey in-
volving key expert stakeholders in the development and
use of clinical trial protocols; 2) a systematic review of
empirical evidence supporting the importance of specific
checklist items; and 3) face-to-face consensus meetings
to develop and finalize the SPIRIT Statement and its
associated explanatory document. This paper describes
in detail the first component of this research.
Methods
The objective of this study was to develop and refine
minimum content for RCT protocols by expert consen-
sus. We conducted a three-round electronic Delphi sur-
vey. Ethics approval was obtained through the Children’s
Hospital of Eastern Ontario.
Selection of participants
Invited expert panellists represented the main stake-
holders involved in clinical trials: investigators, metho-
dologists, statisticians and senior study coordinators
from academia, pharmaceutical industry and govern-
ment; REC/IRB members; members of funding and
regulatory agencies; and major healthcare journal edi-
tors. Experts had to meet the following predefined cri-
teria [21]: relevant knowledge and experience; capacity,
willingness and sufficient time to participate; and ability
to communicate effectively in English. Participants were
selected based on expertise and, where possible, were
ranked and selected according to objective criteria(trialists were required to be an author on a minimum
of five English-language RCT publications over the past
10 years).
We identified potential panellists using a multistep,
iterative approach [22], which included nomination/
snowballing, authors of relevant methodological re-
search and the Institute for Scientific Information’s
‘Highly cited researchers in clinical medicine’ [23]. This
search was supplemented by specific location-based
PubMed searches and targeted Internet searching to
increase geographical distribution and areas of panellist
expertise. Our objective was to include approximately
100 panellists (40 trialists/clinicians, 20 methodologists,
15 study coordinators, 10 ethics board heads/members,
10 funding/regulatory agency representatives and 5
healthcare journal editors) to enable detection of any
divergent opinions between experts groups.
Selection of preliminary items
An initial list of 59 potential checklist items was col-
lated based on existing protocol guidance [19] and
known empirical evidence. Items were grouped under
the following broad headings: a) General information;
b) Introduction; c) Methods; d) Trial organization and
administration; e) Ethical considerations; f ) Reporting
and dissemination; and g) Other. Each item included a
heading and description; wording and structure were
kept similar to existing guidelines, where possible.
Delphi survey
All correspondence occurred via email or facsimile. Ap-
proximately two weeks before the survey was adminis-
tered (August 2007), we informed potential participants
of the objectives of the SPIRIT Initiative and Delphi
process, and invited them to participate. We solicited
reasons for declining, where relevant. Participant ano-
nymity and confidentiality of responses were ensured;
individual responses were known only to the moderator
(JT). Each survey round was conducted over five to six
weeks: one week for pilot testing, three weeks for re-
sponse acquisition (including two reminders prior to the
round closing date) and one week for collating the
results and preparing the subsequent round.
Each candidate item was rated in at least two rounds. In
each round, respondents were asked to rate items on a 10-
point scale (or ‘No judgement’) for their suitability for in-
clusion in a minimum checklist for RCT protocols. A rat-
ing of one corresponded to ‘unimportant - should be
dropped as an item to consider’ and ten corresponded to
‘very important - must be included’. We provided panel-
lists with a space following each item and encouraged
them to add free text comments, suggest reiterations or
suggest additional items they felt would be of benefit for
inclusion in the SPIRIT checklist, if relevant. Round 1 also
Tetzlaff et al. Trials 2012, 13:176 Page 3 of 10
http://www.trialsjournal.com/content/13/1/176collected demographic information (occupation/field and
place of employment) and panellists’ self-rated level of ex-
pertise in participating in this process.
Round 2 of the survey contained all Round 1 items
grouped categorically by median scores rounded to the
nearest whole number (median ≥ 8; 6 ≤median ≥ 7; me-
dian ≤ 5). No changes were made to checklist items,
aside from the addition of newly nominated items from
Round 1, which were drafted to include a heading and
description; as before, wording and structure were kept
similar to existing guidelines, where possible. For each
item, panellists were provided with their previous rating,
group summary ratings (medians, interquartile ranges
(IQRs) and frequency distributions) and anonymized free
text comments from Round 1 (Figure 1). They were
asked to re-rate the items and respond to existing com-
ments, if desired. Panellists were informed that, follow-
ing Round 2, consensus would be defined by the
consistency of median scores between rounds (median ≥
8 = high importance, median ≤ 5 = low importance) and
the absence of significant issues noted in text comments.
The third and final round presented results of items
reaching consensus (Parts 1 and 2) and three sections
requiring additional feedback. Part 3 included items
introduced in Round 2 (to be rated as before: from 1 to
10). Parts 4 and 5 included items requiring a third round
of feedback: those rated of moderate importance (me-
dian 6 to 7) after two rounds (Part 4; Figure 2a) and
items where comments suggested that single items con-
tained multiple concepts of differing importance (Part 5;
Figure 2b). For the latter, concepts were delineated and
respondents were asked to rate each subitem separately.
Each item in Parts 4 and 5 had the following response
options: ‘Include’, ‘Exclude’ or ‘Unsure’.Analysis
Medians and IQRs were calculated for each item. Sub-
group analyses were explored by respondents’ occupa-
tion and self-rated expertise.Figure 1 Example of questionnaire layout from Delphi Round 2.Results
Delphi participants
Invitations to participate in the Delphi survey were sent
(by email) to 167 experts; we received a response from
123 experts, of which 104 (85%) accepted the invitation.
Reasons for declining (n = 19; 15%) were too busy/unable
(n = 15), not interested (n = 1) or no reason provided (n = 3).
Of the panellists agreeing to participate, eight were unable to
respond to either Round 1 or 2 and were not invited to par-
ticipate in Round 3. Thus, ninety-six experts comprised the
final panel.
Panellists met our a priori goals for profession/expertise
representation (Table 1). Eighty-nine (93%) panellists from
17 countries responded to Round 1; 86 (90%) panellists
from 17 countries responded to Round 2; and 84 (88%)
panellists from 16 countries responded to Round 3 of the
survey. Seventy-seven percent responded to all three
rounds, 16% to two rounds and 7% to one round of the
Delphi. Most initiated surveys had 100% completion;
missing data were sparse and were clarified individually
with the respondent.
Delphi results
Figure 3 presents the flow of items through the Delphi
and Tables 2 and 3 present the final results for each con-
cept. In Round 1, respondents collectively rated 56 of the
original 59 items with a median of 8 or greater, three with
a median of 6 or 7 (Personnel, Logistics and Budget) and
none with a median of 5 or less. All items were recircu-
lated in Round 2, where consensus was achieved for 46
(78%) of the original 59 items; 45 items were considered
to be of high importance and 1 (Budget) of low import-
ance. The remaining items - four rated of moderate
importance in Round 2 and nine where comments sug-
gested that clarification was necessary - were recirculated
for Round 3. Of the four rated of moderate importance,
three were ultimately recommended for exclusion
(General Approach, Personnel and Logistics). The fifteen
panellist-nominated items (rated in Rounds 2 and 3;
denoted by § in Tables 2 and 3) included seven with a
Figure 2 Example of questionnaire layout from Delphi Round 3 Parts 4 (A) and 5 (B).
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two with a median of 5 or less (Signatures, Insurance)
Where clarification was required after Round 2 (N = 9
items), panellists’ ratings in Round 3 commonly demon-




Clinical trialist 30 (31)
Healthcare professional 28 (29)
Methodologist 28 (29)
Statistician 16 (17)
Trial coordinator 12 (13)
REC/IRB member 11 (11)
Journal editor 11 (11)
Funding agency representative 5 (5)






Non-profit organization 9 (9)
For-profit organization 4 (4)
Self-employed 0 (0)
Other 5 (5)
Self-perceived level of expertise for survey
High level 49 (51)
Mid-high level 33 (34)
Mid level 8 (8)
Low-mid level 1 (1)
Low-level/no expertise 0 (0)
*Some panellists selected more than one relevant category. REC/IRB, research
ethics committee/institutional review board.(denoted by ‡ in Tables 2 and 3). For example, in gen-
eral, where items requested specific information plus a
justification, respondents strongly favoured the main
concept but not the justification (for example Study
locations (Include (I) = 87%, justification: I = 46%) and
Eligibility criteria (I = 99%, justification: I = 66%)). The
four components of the item Monetary and material
support also received differing levels of support (source
of support: I = 95%; type of support - material, financial:
I = 70%; amount of support: I = 30%; how support is pro-
vided: I = 35%).
Overall, the Delphi panellists rated 63 concepts of high
importance (of which 50 had a lower quartile of 8 or
more), 13 of moderate importance and 12 of low import-
ance for inclusion in a minimum set of concepts for
RCT protocols (Tables 2 and 3). Most items had narrow
IQRs, suggesting agreement between panel members.
However, some items had IQRs that spanned from
recommendations to exclude the item (five or less) to
recommendations to include the item (eight or greater),
such as Reporting of early stopping, Ancillary and substu-
dies, trial Feasibility, Signatures and plans to monitor the
health of pregnant women and their children (Pregnancy).
These items were very often associated with comments
stating that the concept is important but is either too spe-
cific for recommending in a minimum set for all trials or
could be encompassed within another existing item.
Summary of text responses
Many general and item-specific comments were received
during the three survey rounds and were retained for
discussion by the SPIRIT group at subsequent face-to-
face consensus meetings; examples are highlighted here.
In general, many respondents stated that, although
there were many items, most were important and hence
rated highly. While some stated that there must be a
‘balance between guiding researchers and being too pre-
scriptive’, others stated that a comprehensive list is more




Round 2 – 74 items
Round 1 – 59 items





7 ‘ high importance’
7 ‘moderate importance’
5 ‘low importance’  




Figure 3 Flow of items through the Delphi survey.
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trials that ‘deserve(s) a detailed reporting at any stage’. A
few respondents were concerned, however, about the
possible increased burden on trialists. Some suggested
that some concepts may be addressed in associated
documents (for example contracts, statistical and Data
and Safety Monitoring Board (DSMB) charters, labora-
tory manuals) - with reference to such documents in the
protocol - or through other sources (for example web-
sites). Finally, some panellists suggested excluding items
requiring repeated protocol amendments (for example
Personnel, REC/IRB approval) to avoid jeopardizing trial
progress with required official amendments and
resubmissions.
Other general comments related to ambiguity of the
term ‘protocol’, the desired scope of study designs that
the checklist should address, and the potential need to
define intended users of the protocol or checklist. Some
noted that, while all items were potentially important
elements, the importance of some may be relative to the
target end user.
Item-specific comments consisted mostly of explana-
tions to substantiate chosen ratings, suggested revisions,
notes of potential overlap between and opportunities for
merging items (for example Background, Rationale and
Preliminary data; Risks, Harms and Adverse event
reporting), and requests for clarification where items
contained more than one concept or were vague. All
comments were circulated to panellists in each round
and delineations provided, where appropriate, in the final
survey round.
Subgroup analyses
Subgroup analyses showed few differences between
respondents by profession or level of self-perceived ex-
pertise (not shown). As examples, REB/IRB membersand journals editors were more likely than other groups
to support some concepts including a lay summary, a list
of abbreviations, and justifications for study locations or
eligibility criteria. There were no cases of bimodal
results; rather, any differences were in the strength of
support with overlapping IQRs. In some cases, the
subgroup results enabled examination of the potential
validity of additional comments. For example, while some
panellists suggested that the items Logistics and Feasibility
(which received low support overall) would be important
to funding agencies but not to other end users, we found
no difference between the opinions of our expert funding
agency representatives and other groups for these items.
This enabled greater insight and confidence for generating
recommendations from the results.
Discussion
This Delphi survey produced rich information for further
development of the SPIRIT Initiative, which aims to de-
velop a guideline for clinical trial protocol content. Re-
cent studies suggest that PubMed indexes over 6,000
RCTs annually [24] and this number has likely increased
over time [25]. This finding does not account for trials
indexed in other databases (between 20% and 70% of
trials depending on the discipline [26]) and the minimum
of 40% of trials not reaching full publication [27]. Given
that all clinical trials should have a protocol, this Delphi
and the SPIRIT Initiative have broad applicability.
Our panellists rated many concepts as highly import-
ant for inclusion in RCT protocols, most of which had a
strong majority favouring inclusion, indicating consensus
within the panel (for example narrow IQRs). The im-
portance of some of these concepts, such as allocation
concealment, outcomes (including delineation of pri-
mary outcomes), roles of sponsors, and conflicts of
interest, are substantiated by strong empirical evidence
Table 2 Consensus - concepts of ‘high importance’ for minimum protocol content following two or three survey
rounds




Title Descriptive title identifying study design 10 (9,10)
Trial identifier Unique number/name and registration information 10 (9,10)
Protocol version Version or amendment number and date 10 (8,10)
Protocol summary A‡ Short summary of proposed research I = 94; E = 5; U = 1
Names and addresses Names/addresses of primary investigators and sponsor 10 (8,10)
Table of contents List of contents and page numbers 8 (5,9)
Introduction
Rationale Outline topic and provide justification for study 10 (9.5, 10)
Background of the study Summary of all previous studies (that is, a SR or reference) 10 (9,10)
Preliminary data Describe preliminary studies (for example by investigators) 9 (8,10)
Objectives Specific objectives and hypotheses for the study 10 (10,10)
Study location(s) A‡ Description of intended sites(s) I = 87; E = 11; U = 2
Methods
Participants
Population Target and study population and source of the latter 10 (9,10)
Eligibility criteria A‡ Description of inclusion and exclusion criteria (participants) I = 99; E = 1; U = 0
Sample size Estimated number; calculations and assumptions 10 (10,10)
Recruitment Process of recruitment (for example advertisements) and enrolment 9 (8,10)
Design
Type of study Description of type/design and trial framework (for example superiority) 10 (10,10)
Study timeline A‡ Diagram of participants’ procedures and visits through trial stages I = 84; E = 10; U = 6
Sequence generation Method used to generate random sequence; details of any restriction 10 (9,10)
Allocation concealment Method used to implement random sequence and whether concealed 10 (10,10)
Random implementation Who will generate sequence, enrol participants and assign to groups 10 (8,10)
Blinding Who (for example participants/investigators/outcome assessors) 10 (10,10)
Interventions
Interventions A‡ Precise details; how they will be administered (for example dosage, form) I = 99; E = 1; U = 0
Interventions B‡ Justification of control I = 87; E = 8; U = 5
Schedule of interventions Number and duration of treatment periods including run-in, washout 10 (10,10)
Concomitant interventions List of relevant treatments permitted or not before or during trial 10 (9,10)
Risks/Harms Known or potential risks for each study intervention 10 (10,10)
Data collection / management
Outcomes Describe and define primary and secondary outcomes 10 (10,10)
Data collection Methods, instruments and timing of data collection and recording 10 (9,10)
Biological specimens§ Laboratory evaluation, specimen collection, storage and shipping 8 (6,9)
Validation of instruments§ Reliability/validity of instruments or plans to establish validation 8 (6,9)
Follow-up Plans including description and schedule of visits and logistics 10 (9,10)
Data management Plans for data entry, editing, coding and storage 8 (7,9)
Quality control Methods for quality of outcome assessment and data records 9 (8,10)
Compliance Procedures and measures to monitor participant compliance 9 (8,10)
Statistical methods
Statistical methods Methods for primary/secondary outcomes and additional analyses 10 (10,10)
Withdrawals A‡ Criteria to withdraw or exclude participants from the intervention I = 95; E = 2; U = 2
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Table 2 Consensus - concepts of ‘high importance’ for minimum protocol content following two or three survey
rounds (Continued)
Withdrawals B‡ Data to be collected from, and follow-up of, withdrawn participants I = 85; E = 5; U = 10
Missing data Methods to account for missing or erroneous data 9 (8,10)
Interim trial monitoring Process and timing of any planned interim analyses 10 (9,10)
Stopping guidelines A‡ Predefined statistical stopping boundaries I = 92; E = 6; U = 2
Stopping guidelines B‡ Non-statistical criteria for the early trial termination I = 76;E = 12;U = 12
Safety and monitoring
Safety evaluations Plans for monitoring safety including methods and timing. 10 (9,10)
DSMB If relevant, composition and role of DSMB 9 (9,10)
Adverse event reporting Methods of recording/reporting events; methods to deal with them 10 (9,10)
Emergency code-breaking Establishment/storage of code; when and by whom it can be broken 10 (8,10)
Trial monitoring§ Plans and frequency including if independent 8 (6,9)
Trial organization/administration
Monetary/material support A‡ Source(s) of financial and material support I = 94; E = 5; U = 1
Data ownership§ Who has ownership; contractual limits for principal investigators 8 (7,10)
Ethical considerations
Potential benefits and risks Potential benefits and risks to participants and society 10 (9,10)
Agreement and consent Method and person responsible; materials for potential participants 10 (9,10)
Surrogate consent/assent Method of obtaining surrogate consent or assent 10 (9,10)
Confidentiality/Anonymity Provisions for protecting personal data and privacy of participants 10 (9,10)
Ethics approval Whether it has been obtained and name of committees 10 (8,10)
Role of sponsor Role of sponsor in design, data collection, analysis, dissemination 10 (8,10)
Conflict of interest Financial or other real or perceived conflicts of interest 10 (8,10)
Post-trial care§ Post-trial follow-up, access to treatment, duration; who is responsible 8 (6,9)
Reporting and dissemination
Protocol amendments Methods of communicating to investigators/IRBs and documenting 9 (7,10)
Dissemination How results will be disseminated to participants, practitioners, public 8 (7,10)
Publication policy Who has right to publish; restrictions; authorship guidelines 9 (7,10)
Reporting of early stopping§ Dissemination of results if trial is stopped early (for any reason) 8 (5,10)
Other
Limitations Limitations of proposed study, including risk of bias 8 (6,10)
References List of references cited in protocol 10 (9,10)
Data collection forms§ Summary table of all forms to be collected at each time point 8 (6,9)
*Abbreviated version of the full description provided to panellists. †Final results from Round 2 or 3; presented as median (IQR) or % Include (I); % Exclude (E);
% Unsure (U), as relevant. ‡Subconcepts of original items which required delineation in Round 3. §Concepts added by panellists in Round 1 for rating in Round 2
and 3. DSMB, Data and Safety Monitoring Board; SR, systematic review.
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Other concepts are supported by more pragmatic, regu-
latory or ethical rationale. Importantly, many of these
concepts are often not described in protocols of RCTs
[1,3,9,10,35]. This may be, in part, because most existing
protocol content guidelines do not recommend such
concepts [19]. The reasons for the variation between
existing guidelines and our results are unclear as most
guidelines do not report their methods of development.
Our results also indicate where panellists favoured ex-
cluding concepts and where a clear consensus was not
attained. For the former, such as Budget and Logistics,
the lack of support does not suggest that such itemsshould not be included in protocols; only that they may
be context-specific (for example not necessary for journal
publication of protocols) and thus are not appropriate in
a minimum set of requirements. Examples of the latter
include items where wide IQRs remained. We believe that
a systematic review of the methodological literature is im-
portant to complement the Delphi results and to guide
and substantiate final recommendations.
Beyond the utility of the Delphi results for trialists,
REC/IRBs representatives, funding agencies and the
SPIRIT group, this research may be relevant to those
developing reporting guidelines and our experience has
already helped shape the methodology of other ongoing
Table 3 Concepts of ‘moderate’ or ‘low’ importance for minimum protocol content following two or three survey
rounds




Protocol summary B‡ Use of lay/non-technical language I = 63; E = 27; U = 10
List of abbreviations‡ List and descriptors of abbreviations used in protocol I = 74; E = 19; U = 8
Eligibility criteria B Justification of exclusion of subgroups I = 66; E = 28; U =6
Monetary/materials support B‡ List the type(s) of support provided I = 70; E = 21; U = 10
Feasibility§ Acceptability for personnel/participants; capacity for recruitment 6 (3,8)
Co-enrolment in studies§ Regulations pertaining to co-enrolment in other research studies 7 (5,8)
Investigational product(s)§ Formulation, packaging, labeling and supply; accountability 7 (5,9)
Pregnancy§ Monitoring of health of woman and child (short and long term) 7 (4,10)
Ancillary and substudies§ Foreseen future uses of data or biological materials; consent 7 (5,9)
Post-trial data/materials storage§ Data/materials storage: location(s), duration, responsibility 7 (4,8)
Appendix materials A‡ Samples of the standardized case-report forms I = 65; E = 23; U = 12
Appendix materials B‡ Other data collection forms (for example questionnaires) I = 70; E = 21; U = 10
Appendix materials C‡ Consent/assent forms I = 72; E = 23; U = 5
Rated ‘low importance’
General approach‡ Outline the general approach to address the research question I = 52; E = 42; U = 6
Study locations B‡ Briefly justify sites(s) where research is to be conducted I = 46; E = 46; U = 8
Study locations C‡ Relevant demographic/epidemiological information of study region I = 46; E = 47; U = 8
Study timeline B‡ Schematic of the study stages’ expected completion dates I = 58; E = 30; U = 12
Withdrawals C‡ In a multicentre study, when a centre may be discontinued I = 55; E = 30; U = 16
Monetary/materials support C The amount of support provided I = 30; E = 57; U = 13
Monetary/materials support D‡ How support is provided (for example research account, honorarium) I = 35; E = 53; U = 12
Personnel‡ Names, affiliations, contact details of key trial personnel I = 40; E = 51; U = 9
Logistics‡ Availability of resources incl. administration, equipment, facilities I = 27; E = 64; U = 10
Budget Budget for personnel, equipment, facilities and supplies 5 (2,6)
Signatures§ Signatures including principle investigators or chief medical officer 5 (2,8)
Insurance§ Plans including coverage to provide treatment and compensation 5 (2,7)
*Abbreviated version of the full description provided to panellists. †Final results from Round 2 or 3; presented as median (IQR) or % Include (I); % Exclude (E);
% Unsure (U), as relevant. ‡Items requiring additional clarification or subconcepts of original items which required delineation in Round 3. §Concepts added by
panellists in Round 1 for rating in Round 2 and 3.
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adequate time and attention to ensure they meet the cri-
teria suggested by previous guidance [21] as this is pivotal
to both the internal and external validity (generalizability)
of the Delphi results. Future endeavours should also con-
sider empirically supported strategies to help increase re-
sponse rates [36-42] including those used in the current
study: survey prenotification/invitation to participate, per-
sonalized invitations and surveys, notification of and ad-
herence to expected timelines, clear outline of
expectations including time-commitments, written com-
mitment by panellists to participate (reply by email),
follow-up reminders to non-respondents, provision of
previous rounds’ responses and assurance of confidential-
ity. We also pilot tested each round, collected panellists’
comments and employed a flexible survey design. Usingan Internet-based tool may substantially increase Delphi
efficiency and is recommended for future work.
Despite the many benefits of the Delphi consensus
technique, the results are only as valid as the opinions of
the experts constituting the panel. Even if consensus is
attained, validating whether this consensus represents the
‘truth’ is not possible, and we recognize that expert opin-
ion remains among the lowest levels of empirical evi-
dence [43]. To safeguard the validity of our results, we
carefully selected a panel representing key stakeholders.
Structured, predefined methods were employed to
minimize biased response collation. Importantly, our
panellists were experienced and committed to completing
the process, increasing internal validity of the results.
We chose the Delphi consensus method [21] for this
work for several reasons: the research problem was felt
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larger and more diverse group could be consulted than
could effectively meet face-to-face due to expense, size
and the logistics of group interaction; and the preserva-
tion of participant anonymity allowed for open discus-
sion. This method also shares the advantages of other
integrative methods of knowledge translation [44] ideally
resulting in a guideline that, beyond being founded on
transparent and systematic methods, is externally valid
and ultimately meets the needs of end users. We recom-
mend this technique to others embarking on similar
initiatives.
Conclusion
This Delphi consensus has provided a large volume of
rich information to guide the development of the SPIRIT
checklist, an evidence-based guideline for the content of
trial protocols. By applying a formal consensus method
and engaging experts from diverse areas, the results of
which will be complemented by empirical evidence from
the methodological literature, the aim is to collate guid-
ance on important concepts to address in protocols. The
SPIRIT Initiative ultimately aspires to help increase trans-
parency and completeness of information in trial proto-
cols, ideally helping to improve the reliability and validity
of the medical literature guiding healthcare decisions.
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